Two Sigma Advisers LP Has $666,000 Holdings in Accolade, Inc. (NASDAQ:ACCD)

Two Sigma Advisers LP increased its position in shares of Accolade, Inc. (NASDAQ:ACCD) by 322.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 194,800 shares of the company’s stock after acquiring an additional 148,700 shares during the quarter. Two Sigma Advisers LP owned 0.24% of Accolade worth $666,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. SG Americas Securities LLC increased its stake in Accolade by 36.1% in the 4th quarter. SG Americas Securities LLC now owns 40,498 shares of the company’s stock valued at $139,000 after buying an additional 10,749 shares during the period. Savant Capital LLC increased its stake in Accolade by 182.1% in the 4th quarter. Savant Capital LLC now owns 52,794 shares of the company’s stock valued at $181,000 after buying an additional 34,082 shares during the period. Fairman Group LLC increased its stake in Accolade by 58.5% in the 4th quarter. Fairman Group LLC now owns 1,802,399 shares of the company’s stock valued at $6,164,000 after buying an additional 665,112 shares during the period. Rhumbline Advisers increased its stake in Accolade by 1.7% in the 4th quarter. Rhumbline Advisers now owns 115,136 shares of the company’s stock valued at $394,000 after buying an additional 1,967 shares during the period. Finally, Ieq Capital LLC increased its stake in Accolade by 99.1% in the 4th quarter. Ieq Capital LLC now owns 82,509 shares of the company’s stock valued at $282,000 after buying an additional 41,071 shares during the period. Institutional investors and hedge funds own 84.99% of the company’s stock.

Accolade Stock Performance

Shares of ACCD opened at $7.02 on Wednesday. The company’s fifty day moving average is $7.02 and its 200-day moving average is $6.09. Accolade, Inc. has a 12 month low of $3.08 and a 12 month high of $7.03. The firm has a market cap of $575.59 million, a price-to-earnings ratio of -3.12 and a beta of 2.10. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67.

Wall Street Analysts Forecast Growth

ACCD has been the topic of several research reports. Piper Sandler lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Stephens reiterated an “equal weight” rating and issued a $7.03 price objective on shares of Accolade in a research note on Wednesday, February 12th. Thirteen analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.51.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.